KLRA Stock Forecast: Kailera Therapeutics, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Kailera Therapeutics, Inc. hold a median 12-month price target of $42 — +142.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
KLRA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Kailera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (35): Smaller than most of the companies we track.
Volatility (3): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Kailera Therapeutics, Inc. — and when they’d sell — is the membership.
KLRA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KLRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +142.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 May 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 12 May 2026 | Jefferies | Initiates | Buy | $48 |
| 12 May 2026 | JP Morgan | Initiates | Overweight | $30 |
| 12 May 2026 | Leerink Partners | Initiates | Outperform | $36 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KLRA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Kailera Therapeutics, Inc. (KLRA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −13.4×
- Price / sales
- —
- Price / book
- −4.6×
- EV / EBITDA
- −12.1×
Cheaper than 94% of US stocks
Cheaper than 96% of US stocks
Cheaper than 86% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 41.8%
- Return on assets
- −21.5%
- Dividend yield
- —
Higher than 92% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
KLRA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KLRA appears on the weeks it earns a place.
Frequently asked questions about KLRA stock
What is the KLRA stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Kailera Therapeutics, Inc. have a median 12-month price target of $42, with estimates ranging from $30 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KLRA stock a buy right now?
Of the 6 analysts covering Kailera Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kailera Therapeutics, Inc. 1 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KLRA?
As at 1 Aug 2026, Kailera Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (35 of 100).
Will KLRA stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +142.5% from the last close, and Ticker Nerd's factor model ranks Kailera Therapeutics, Inc. 1 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KLRA stock forecast for 2030?
No analyst covering Kailera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KLRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $57 over the next 12 months.
What does Kailera Therapeutics, Inc. do?
Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on developing a diversified pipeline of GLP-1 therapies for obesity treatment. Headquartered in Waltham, Massachusetts, the company advances multiple clinical programs including ribupatide, its lead product candidate that functions as a once-weekly injectable GLP-1/GIP receptor dual agonist peptide currently in global Phase 3 trials.
About Kailera Therapeutics, Inc.
Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on developing a diversified pipeline of GLP-1 therapies for obesity treatment. Headquartered in Waltham, Massachusetts, the company advances multiple clinical programs including ribupatide, its lead product candidate that functions as a once-weekly injectable GLP-1/GIP receptor dual agonist peptide currently in global Phase 3 trials. The company also develops oral and injectable formulations targeting various stages of obesity treatment, including KAI-7535, an oral small-molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera holds exclusive worldwide rights outside of China, Hong Kong, Macau, and Taiwan for its therapeutic candidates licensed from Jiangsu Hengrui Pharmaceuticals. The company recently completed its initial public offering and operates within the healthcare biotechnology sector, addressing obesity as a chronic progressive disease affecting over one billion people globally.
CEO Mr. Ronald C. Renaud Jr., M.B.A. · 145 employees · United States · https://www.kailera.com